Physician profile

Jacob Anthony Panici

Primary Podiatric Medicine · Cary, NC

NPI 1255773222

$13,105.49

in general payments reported to CMS, 2019-2025

44 companies · $905 in 2025

The $905 reported for 2025 was more than what 86% of Primary Podiatric Medicine providers received nationally (typical 2025 total: $232).

See the full distribution for Primary Podiatric Medicine

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$4,033.36
Travel and Lodging$78.00

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Arthrex, INC. $3,146.24 2020
Musculoskeletal Transplant Foundation INC. $1,298.79 2019-2023
Convatec INC. $1,118.25 2023
Southtech Orthopedics $876.18 2020
Epsfl, LLC $725.91 2023
Smith+Nephew, INC. $702.57 2019-2023 Grafix Pl, Stravix Pl, Grafix
Next Science LLC $581.71 2022-2023 Blastx, Xperience, Surgx
Globus Medical, INC. $458.95 2025 Senza
Organogenesis INC. $408.46 2019-2025 Puraply, Apligraf
Kerecis Limited $377.54 2020-2025 Kerecis Surgiclose, Kerecis Graftguide
Paratek Pharmaceuticals, INC. $371.24 2021-2023 Nuzyra
Horizon Therapeutics Plc $297.47 2020-2023 Krystexxa
Zimmer Biomet Holdings, INC. $278.17 2019-2023 Tapestry, Nextremity General Instrument, Stratum Foot Plating System
Stryker Corporation $277.07 2019-2023 Easyfuse, Augment Injectable, Citrefix
Amniox Medical, INC. $255.21 2019
Show all 44 companies
CompanyGeneral paymentsYearsTop products
Bioventus LLC $223.96 2022-2024 Exogen Ultrasound Bone Healing System
Lifenet Health $149.10 2025 Theragenesis Wound Matrix
Integra Lifesciences Corporation $144.10 2021
Forma Medical $142.50 2024 Optimalakin
Linvatec Corporation $136.69 2025 Biobrace 23mm, Rts, Neospan
Osiris Therapeutics INC. $136.23 2019
In2bones USA, LLC $134.24 2019
Ossio INC $119.96 2022
Cardiovascular Systems INC. $107.71 2021
Angiodynamics, INC. $93.72 2022
Nevro Corp. $60.04 2022-2024 Senza
Fidia Pharma USA INC. $46.12 2021-2022
Ortho Dermatologics, A Division of Bausch Health US, LLC $41.56 2023 Jublia
Kci USA, INC. $41.35 2019-2022
Merck Sharp & Dohme LLC $40.96 2019
Aroa Biosurgery Incorporated $40.11 2019
Djo, LLC $37.06 2019-2021
Zyla Life Sciences, INC. $28.16 2019-2020
Kowa Pharmaceuticals America, INC. $26.95 2022-2023 Seglentis
Janssen Pharmaceuticals, INC $24.71 2021
Triad Life Sciences INC. $24.41 2022
Grt US Holding, INC. $24.24 2022
Wright Medical Technology, INC. $19.70 2020
Acumed LLC $19.11 2024 Osteomed, Acumed
Normatec Industries, LP $17.80 2019
Treace Medical Concepts, INC. $15.52 2022
Polarityte, INC. $13.46 2019
Melinta Therapeutics, LLC $11.17 2019
Depuy Synthes Sales INC. $11.09 2020

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Jacob Anthony Panici

$13,105.49

in general payments reported 2019-2025

Years
2019-2025
Top company
Arthrex, INC.
Context
The $905 reported for 2025 was more than what 86% of Primary Podiatric Medicine providers received nationally (typical 2025 total: $232).

https://glasscript.com/doctor/1168108/jacob-anthony-panici

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.